Nikki J
Moderator
- Joined
- Mar 22, 2012
- Messages
- 16,475
- Reason
- PALS
- Diagnosis
- 04/2014
- Country
- US
- State
- MA
- City
- Boston
failed to show an effect on biomarkers in a small trial in NY and Boston
The study concludes that following treatment with MN-166 (ibudilast) in ALS participants, there were no (a) detectable biological impact of MN-166 up to 100mg/day dosages on lowering brain inflammation measured by PBR28-PET SUVR over 12–24 weeks (N=22 participants) or (b) lowering disease activity as measured by blood neurofilament light levels over 36–40 weeks (N=10 participants). Dose reductions and discontinuations due to treatment emergent adverse events were common at this dosage (100mg/day) in ALS participants.
they said this was not a clinical efficacy study and one is planned but the no effect on brain inflammation or nf levels even at 100 mg is discouraging
The study concludes that following treatment with MN-166 (ibudilast) in ALS participants, there were no (a) detectable biological impact of MN-166 up to 100mg/day dosages on lowering brain inflammation measured by PBR28-PET SUVR over 12–24 weeks (N=22 participants) or (b) lowering disease activity as measured by blood neurofilament light levels over 36–40 weeks (N=10 participants). Dose reductions and discontinuations due to treatment emergent adverse events were common at this dosage (100mg/day) in ALS participants.
they said this was not a clinical efficacy study and one is planned but the no effect on brain inflammation or nf levels even at 100 mg is discouraging
